Aurobindo Pharma shares end with 3% gains on USFDA nod

pharma_jpg_2783600eIn this November 11, 2014, A view of the new building of Aurobindo Pharma office at Madhapur in Hyderabad.

“The company has received final approval from the US Food and Drug Administration to manufacture and market Naproxen Sodium tablets USP, 220 mg,” Aurobindo Pharma had said in a BSE filing on Saturday.

Shares of Aurobindo Pharma ended with 3 per cent gains on Monday after the company got final approval from the USFDA to manufacture and market its generic Naproxen Sodium tablets for treating osteoporosis.

The stock went up by 3.06 per cent to settle at Rs 742.95 on BSE. During the day, it climbed 3.78 per cent to Rs 748.20.

On NSE, shares of the company jumped 3 per cent to close at Rs 743.

The firm added Rs 1,377.17 crore to its market valuation which reached Rs 43,475.17 crore.

On the volume front, 4.51 lakh shares of the company changed hands at BSE and over 21 lakh shares were traded at NSE during the day.

“The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Naproxen Sodium tablets USP, 220 mg,” Aurobindo Pharma had said in a BSE filing on Saturday.

“The product is expected to be launched in Q1 of 2016—17,” it had said.

Pin It

Leave a Reply

Your email address will not be published. Required fields are marked *